MKI67 and neoplasm: Consistent with in vitro data, immunohistochemistry, TUNEL analyses, and the overall survival rate (Figure 7B–D) of xenograft tumors revealed that the momelotinib and sorafenib combination effectively inhibited the expression of Ki-67, a marker for representing tumor proliferation.